Trial Profile
An Open Label, Multicenter, Randomized, Uncontrolled Study Assessing the Safety and Efficacy of KH902 in Patients With Choroidal Neovascularization Due to Neovascular Age-related Macular Degeneration(HOPE Study)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Nov 2020
Price :
$35
*
At a glance
- Drugs Conbercept (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms HOPE study
- Sponsors Chengdu Kanghong Biological Science & Technology
- 01 Sep 2014 New trial record